Baring Private Equity Asia (BPEA) has invested $100m in HUTCHMED (Hutchison China MediTech) via a private placement. The new shares, in the form of 3.28m ADS (each equivalent to five ordinary shares), are priced at $30.50 per ADS, a 7% premium over the prior close. HUTCHMED will receive the full proceeds of the placing, which will be employed for the continued development of its clinical pipeline and building the commercial infrastructure both in China and globally.
08 Apr 2021
Baring Private Equity Asia invests $100m
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Baring Private Equity Asia invests $100m
HUTCHMED (China) Limited (HCM:LON) | 0 0 (-0.4%) | Mkt Cap: 2,326m
- Published:
08 Apr 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Baring Private Equity Asia (BPEA) has invested $100m in HUTCHMED (Hutchison China MediTech) via a private placement. The new shares, in the form of 3.28m ADS (each equivalent to five ordinary shares), are priced at $30.50 per ADS, a 7% premium over the prior close. HUTCHMED will receive the full proceeds of the placing, which will be employed for the continued development of its clinical pipeline and building the commercial infrastructure both in China and globally.